US Stock MarketDetailed Quotes

FATE Fate Therapeutics

Watchlist
  • 1.610
  • -0.010-0.62%
Close Dec 27 16:00 ET
  • 1.610
  • 0.000-0.01%
Post 18:35 ET
183.37MMarket Cap-0.98P/E (TTM)

Fate Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
58.13%3.07M
625.83%6.77M
-96.74%1.93M
-34.03%63.53M
-96.22%1.68M
-87.02%1.94M
-94.97%933K
220.30%58.98M
72.44%96.3M
159.86%44.36M
Operating revenue
58.13%3.07M
625.83%6.77M
-96.74%1.93M
-34.03%63.53M
-96.22%1.68M
-87.02%1.94M
-94.97%933K
220.30%58.98M
72.44%96.3M
159.86%44.36M
Cost of revenue
Gross profit
Operating expense
4.19%55.45M
-18.34%51.86M
-39.49%52.99M
-37.22%254.04M
-54.26%49.75M
-47.50%53.22M
-37.54%63.5M
-5.72%87.57M
48.32%404.69M
25.82%108.78M
Selling and administrative expenses
9.78%20.8M
-23.74%17.25M
-4.96%20.86M
-3.31%81.45M
-16.91%17.94M
-12.09%18.95M
11.16%22.62M
5.79%21.94M
46.95%84.23M
27.44%21.58M
-General and administrative expense
9.78%20.8M
-23.74%17.25M
-4.96%20.86M
-3.31%81.45M
-16.91%17.94M
-12.09%18.95M
11.16%22.62M
5.79%21.94M
46.95%84.23M
27.44%21.58M
Research and development costs
1.09%34.65M
-15.34%34.6M
-51.03%32.14M
-46.14%172.6M
-63.51%31.82M
-57.06%34.28M
-49.73%40.88M
-9.02%65.63M
48.69%320.45M
25.43%87.19M
Operating profit
-2.14%-52.38M
27.94%-45.08M
-78.61%-51.07M
38.22%-190.51M
25.37%-48.08M
40.64%-51.28M
24.72%-62.57M
61.60%-28.59M
-42.12%-308.39M
7.15%-64.42M
Net non-operating interest income expense
-5.51%4.44M
10.18%4.83M
12.32%4.15M
194.18%17.19M
53.26%4.41M
162.84%4.7M
478.73%4.38M
783.73%3.69M
346.29%5.84M
869.70%2.88M
Non-operating interest income
-5.51%4.44M
10.18%4.83M
12.32%4.15M
194.18%17.19M
53.26%4.41M
162.84%4.7M
478.73%4.38M
783.73%3.69M
346.29%5.84M
869.70%2.88M
Other net income (expense)
-81.52%261K
-66.31%1.83M
-118.03%-1.09M
-40.46%12.4M
-108.91%-461K
35.64%1.41M
-13.09%5.43M
-28.02%6.02M
489.22%20.82M
1,015.52%5.18M
Gain on sale of security
----
----
----
-87.62%2.52M
----
----
----
----
474.62%20.31M
----
Other non- operating income (expenses)
-81.52%261K
-66.31%1.83M
-118.03%-1.09M
1,815.12%9.88M
80.33%-2.98M
35.64%1.41M
-13.09%5.43M
-28.02%6.02M
--516K
---15.13M
Income before tax
-5.55%-47.68M
27.16%-38.43M
-154.25%-48M
42.88%-160.93M
21.72%-44.12M
45.94%-45.17M
30.68%-52.76M
71.26%-18.88M
-32.79%-281.72M
17.86%-56.36M
Income tax
Net income
-5.55%-47.68M
27.16%-38.43M
-154.25%-48M
42.88%-160.93M
21.72%-44.12M
45.94%-45.17M
30.68%-52.76M
71.26%-18.88M
-32.79%-281.72M
17.86%-56.36M
Net income continuous Operations
-5.55%-47.68M
27.16%-38.43M
-154.25%-48M
42.88%-160.93M
21.72%-44.12M
45.94%-45.17M
30.68%-52.76M
71.26%-18.88M
-32.79%-281.72M
17.86%-56.36M
Minority interest income
Net income attributable to the parent company
-5.55%-47.68M
27.16%-38.43M
-154.25%-48M
42.88%-160.93M
21.72%-44.12M
45.94%-45.17M
30.68%-52.76M
71.26%-18.88M
-32.79%-281.72M
17.86%-56.36M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-5.55%-47.68M
27.16%-38.43M
-154.25%-48M
42.88%-160.93M
21.72%-44.12M
45.94%-45.17M
30.68%-52.76M
71.26%-18.88M
-32.79%-281.72M
17.86%-56.36M
Basic earnings per share
13.04%-0.4
38.89%-0.33
-147.37%-0.47
43.64%-1.64
22.41%-0.45
46.51%-0.46
31.65%-0.54
72.06%-0.19
-29.91%-2.91
19.44%-0.58
Diluted earnings per share
13.04%-0.4
38.89%-0.33
-147.37%-0.47
43.64%-1.64
22.41%-0.45
46.51%-0.46
31.65%-0.54
72.06%-0.19
-29.91%-2.91
19.44%-0.58
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 58.13%3.07M625.83%6.77M-96.74%1.93M-34.03%63.53M-96.22%1.68M-87.02%1.94M-94.97%933K220.30%58.98M72.44%96.3M159.86%44.36M
Operating revenue 58.13%3.07M625.83%6.77M-96.74%1.93M-34.03%63.53M-96.22%1.68M-87.02%1.94M-94.97%933K220.30%58.98M72.44%96.3M159.86%44.36M
Cost of revenue
Gross profit
Operating expense 4.19%55.45M-18.34%51.86M-39.49%52.99M-37.22%254.04M-54.26%49.75M-47.50%53.22M-37.54%63.5M-5.72%87.57M48.32%404.69M25.82%108.78M
Selling and administrative expenses 9.78%20.8M-23.74%17.25M-4.96%20.86M-3.31%81.45M-16.91%17.94M-12.09%18.95M11.16%22.62M5.79%21.94M46.95%84.23M27.44%21.58M
-General and administrative expense 9.78%20.8M-23.74%17.25M-4.96%20.86M-3.31%81.45M-16.91%17.94M-12.09%18.95M11.16%22.62M5.79%21.94M46.95%84.23M27.44%21.58M
Research and development costs 1.09%34.65M-15.34%34.6M-51.03%32.14M-46.14%172.6M-63.51%31.82M-57.06%34.28M-49.73%40.88M-9.02%65.63M48.69%320.45M25.43%87.19M
Operating profit -2.14%-52.38M27.94%-45.08M-78.61%-51.07M38.22%-190.51M25.37%-48.08M40.64%-51.28M24.72%-62.57M61.60%-28.59M-42.12%-308.39M7.15%-64.42M
Net non-operating interest income expense -5.51%4.44M10.18%4.83M12.32%4.15M194.18%17.19M53.26%4.41M162.84%4.7M478.73%4.38M783.73%3.69M346.29%5.84M869.70%2.88M
Non-operating interest income -5.51%4.44M10.18%4.83M12.32%4.15M194.18%17.19M53.26%4.41M162.84%4.7M478.73%4.38M783.73%3.69M346.29%5.84M869.70%2.88M
Other net income (expense) -81.52%261K-66.31%1.83M-118.03%-1.09M-40.46%12.4M-108.91%-461K35.64%1.41M-13.09%5.43M-28.02%6.02M489.22%20.82M1,015.52%5.18M
Gain on sale of security -------------87.62%2.52M----------------474.62%20.31M----
Other non- operating income (expenses) -81.52%261K-66.31%1.83M-118.03%-1.09M1,815.12%9.88M80.33%-2.98M35.64%1.41M-13.09%5.43M-28.02%6.02M--516K---15.13M
Income before tax -5.55%-47.68M27.16%-38.43M-154.25%-48M42.88%-160.93M21.72%-44.12M45.94%-45.17M30.68%-52.76M71.26%-18.88M-32.79%-281.72M17.86%-56.36M
Income tax
Net income -5.55%-47.68M27.16%-38.43M-154.25%-48M42.88%-160.93M21.72%-44.12M45.94%-45.17M30.68%-52.76M71.26%-18.88M-32.79%-281.72M17.86%-56.36M
Net income continuous Operations -5.55%-47.68M27.16%-38.43M-154.25%-48M42.88%-160.93M21.72%-44.12M45.94%-45.17M30.68%-52.76M71.26%-18.88M-32.79%-281.72M17.86%-56.36M
Minority interest income
Net income attributable to the parent company -5.55%-47.68M27.16%-38.43M-154.25%-48M42.88%-160.93M21.72%-44.12M45.94%-45.17M30.68%-52.76M71.26%-18.88M-32.79%-281.72M17.86%-56.36M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -5.55%-47.68M27.16%-38.43M-154.25%-48M42.88%-160.93M21.72%-44.12M45.94%-45.17M30.68%-52.76M71.26%-18.88M-32.79%-281.72M17.86%-56.36M
Basic earnings per share 13.04%-0.438.89%-0.33-147.37%-0.4743.64%-1.6422.41%-0.4546.51%-0.4631.65%-0.5472.06%-0.19-29.91%-2.9119.44%-0.58
Diluted earnings per share 13.04%-0.438.89%-0.33-147.37%-0.4743.64%-1.6422.41%-0.4546.51%-0.4631.65%-0.5472.06%-0.19-29.91%-2.9119.44%-0.58
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion------------
Trending US Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
+0.58%
Halozyme Therapeutics
HALO
+0.21%
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
0.00%
YETI Holdings
YETI
-0.08%
Dorian LPG
LPG
-0.25%

Unlock the Full List